Key Takeaways
- • Neko Health closed a $700 million Series C funding round led by Lightspeed Venture Partners and O.G. Venture Partners, positioning the Swedish preventive health startup for U.S. market entry with a planned New York City clinic launch later in 2026.
- • The company, founded by Daniel Ek (Spotify founder) and Hjalmar Nilsonne, utilizes proprietary non-invasive, radiation-free scanning technology that captures millions of health data points across skin, cardiovascular, blood, and metabolic health without traditional MRI equipment.
- • High-profile backers include celebrities and billionaires Claudia Schiffer, Maria Sharapova, Mark Zuckerberg, Priscilla Chan, Jimmy Iovine, Danny Meyer, Thierry Henry, and Tim Ferriss, alongside institutional investors Atomico, General Catalyst, and Lakestar.
- • Neko Health's scanning service is priced at £299 (approximately $341 USD) in the U.K. market; U.S. pricing has not been disclosed. The platform now integrates wearables data and body composition analysis alongside its core diagnostic capabilities.
- • The funding validates demand for preventive health diagnostics that compete with established players like Prenuvo and Ezra (now owned by Function Health), addressing a market gap for accessible, non-radiation-based full-body health assessment.
Summary
Neko Health, the Swedish health-technology startup founded by Spotify's Daniel Ek and Hjalmar Nilsonne, has secured $700 million in Series C funding to accelerate its entry into the U.S. market. The round was co-led by venture firms Lightspeed Venture Partners and O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst, and Lakestar, alongside new backers including Liberty City Ventures, Positive Sum, and BDT & MSD. David Ofer of O.G. Venture Partners will join the company's board as part of the investment.
The funding round is notable for its assembly of celebrity and billionaire backers, including Mark Zuckerberg and Priscilla Chan, Claudia Schiffer, Maria Sharapova, Jimmy Iovine, Danny Meyer, Thierry Henry, and Tim Ferriss, signaling institutional and high-net-worth confidence in the preventive health screening market. This capital influx supports Neko Health's expansion into the United States, with the company planning to launch its first U.S. clinic in New York City later in 2026.
Neko Health's core offering is a non-invasive, radiation-free diagnostic scanning platform that generates proprietary data across skin health, cardiovascular function, blood biomarkers, and metabolic indicators. Unlike competitors such as Prenuvo and Ezra (acquired by Function Health), the company does not rely on traditional large-scale medical imaging machines like MRIs. The platform uses proprietary sensors and blood analysis to assess risks for pre-diabetes, metabolic syndrome, stroke, and heart disease, delivering on-site results and in-person medical consultations. Recent platform upgrades now include wearables integration and body composition analysis.
In the U.K., Neko Health prices its scans at £299 (approximately $341 USD at current exchange rates), though the company has not announced U.S. pricing. The startup has completed over 10,000 scans across its European operations and positions itself in the growing preventive health diagnostics segment, which targets affluent consumers seeking comprehensive health assessment without radiation exposure.
The funding round is notable for its assembly of celebrity and billionaire backers, including Mark Zuckerberg and Priscilla Chan, Claudia Schiffer, Maria Sharapova, Jimmy Iovine, Danny Meyer, Thierry Henry, and Tim Ferriss, signaling institutional and high-net-worth confidence in the preventive health screening market. This capital influx supports Neko Health's expansion into the United States, with the company planning to launch its first U.S. clinic in New York City later in 2026.
Neko Health's core offering is a non-invasive, radiation-free diagnostic scanning platform that generates proprietary data across skin health, cardiovascular function, blood biomarkers, and metabolic indicators. Unlike competitors such as Prenuvo and Ezra (acquired by Function Health), the company does not rely on traditional large-scale medical imaging machines like MRIs. The platform uses proprietary sensors and blood analysis to assess risks for pre-diabetes, metabolic syndrome, stroke, and heart disease, delivering on-site results and in-person medical consultations. Recent platform upgrades now include wearables integration and body composition analysis.
In the U.K., Neko Health prices its scans at £299 (approximately $341 USD at current exchange rates), though the company has not announced U.S. pricing. The startup has completed over 10,000 scans across its European operations and positions itself in the growing preventive health diagnostics segment, which targets affluent consumers seeking comprehensive health assessment without radiation exposure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.